Skip to content

Lenograstim

    Brands

    Lenograstim

    DAE Class; Rx

    Common Brand Names; GRANOCYTE-34

    • Anabolics & hematopoietics

    Lenograstim is a recombinant human granulocyte-colony stimulating factor (rhG-CSF) that stimulates the production of neutrophils and may reduce the duration of chemotherapy-induced neutropeniaand there by reduce the incidence of associated sepsis; there is yet no evidence thet it improvesoverall survival.

    Lenograstim is primarily indicated in conditions like Bone marrow transplantation, Cytotoxic-induced neutropenia, Mobilisation of peripheral blood progenitor cells, Neutropenia, Reduction in the duration of neutropenia following bone marrow transplantation

    Lenograstim is contraindicated in conditions like Kostmans syndrome.

    The severe or irreversible adverse effects of Lenograstim, which give rise to further complications include Anemia, Anemia, Thrombocytopenia, Disturbed hepatic function, Disturbed hepatic function, Anemia, Anemia.

    The symptomatic adverse reactions produced by Lenograstim are more or less tolerable and if they become severe, they can be treated symptomatically, these include Headache, Diarrhea, Hypotension, Bone pain, Vasculitis, Uricemia, Proteinuria, Musculoskeletal pain, Epistaxis.

    Caution should be taken if tumours with myeloid characteristics (risk of the tumour growth), pre-malignant myeloid conditions is present. Reduced myeloid precursors, monitor leucocyte count (discontinue treatment if leucocylossis); monitor platelet count and hemoglobin; regular morphological and cytogenetic bone marrow examinations recommended in severe congenital neutropenia (possible risk of myelodysplastic syndromes or leukemia) monitor spleen size, osteoporotic bone disease ( monitor bone marrow densityif given for more than 6 months).

    No Information regarding High Risk Group is available.

    Neutropenia following bone marrow transplantation

    Adult: 150 mcg/m2 (19.2 million IU/m2) daily given via IV infusion over 30 minutes or via SC inj, to be started the day (not less than 24 hours) after transplantation and continued until the expected nadir has passed and the neutrophil count has stabilised. Max duration: 28 days.
    Child: >2 years Same as adult dose.


    Subcutaneous
    Mobilisation of peripheral blood progenitor cells for autologous peripheral blood stem cell transplantation

    Adult: As monotherapy: 10 mcg/kg (1.28 million IU/kg) daily for 4-6 days (5-6 days in healthy donors). After myelosuppressive chemotherapy: 150 mcg/m2 (19.2 million IU/m2) daily, to be started 1-5 days after completion of chemotherapy and continued until the neutrophil count has stabilised.


    Subcutaneous
    Chemotherapy-induced neutropenia

    Adult: 150 mcg/m2 (19.2 million IU/m2) daily, to be started on the day (not less than 24 hours) after the last dose of antineoplastic and continued until the expected nadir has passed and the neutrophil count has stabilised. Max duration: 28 days.
    Child: >2 years Same as adult dose.

    Lenograstim

    Inj: 33.6 MIU